OBJECTIVES
To assess the impact of new rules for pharmacoeconomic evaluations in Serbia, after the publishing of a new rulebook covering the criteria, methods and conditions for listing medicines.
METHODS
We investigated the budget impact analysis made by pharmaceutical companies, in the period September 2013 to June 2014. Quality was assessed using the criteria for pharmacoeconomic evaluations from the in the most recent ISPOR guidelines and the Serbian pharmacoeconomic guidelines. The impact of the introduction of the new rulebook was assessed by comparing the period following its introduction with the number and quality of submissions in the preceding period. 
RESULTS

Between
CONCLUSION
The introduction of compulsory pharmacoeconomic component to reimbursement submissions in Serbia has raised the standard of submissions for listing the medicines for reimbursement. This standard is still too low to fully facilitate transparent evidence based decision making, however the new rulebook is expected to force both the national fund and the pharmaceutical industry to increase their skills in evidence based decision making. However, Serbia still suffers from a lack of the information required to construct quality pharmacoeconomic analysis, with limited local cost estimates available and limited supply of health economic skills in the region. 
